Biosimilar drugs' global revenues “to hit $2.44B this year" PharmaTimes From 2014, many companies will be trying to launch mAb biosimilar products, and the majority will be targeting Roche's Rituxan (rituximab) and Herceptin (trastuzumab), and Johnson & Johnson/Merck & Co/Mitsubishi Tanabe's Remicade (inflximab) for ... |
